Rational Polypharmacology: Systematically Identifying and Engaging Multiple Drug Targets To Promote Axon Growth.

Mammalian central nervous system (CNS) neurons regrow their axons poorly following injury, resulting in irreversible functional losses. Identifying therapeutics that encourage CNS axon repair has been difficult, in part because multiple etiologies underlie this regenerative failure. This suggests a particular need for drugs that engage multiple molecular targets. Although multitarget drugs are generally more effective than highly selective alternatives, we lack systematic methods for discovering such drugs. Target-based screening is an efficient technique for identifying potent modulators of individual targets. In contrast, phenotypic screening can identify drugs with multiple targets; however, these targets remain unknown. To address this gap, we combined the two drug discovery approaches using machine learning and information theory. We screened compounds in a phenotypic assay with primary CNS neurons and also in a panel of kinase enzyme assays. We used learning algorithms to relate the compounds' kinase inhibition profiles to their influence on neurite outgrowth. This allowed us to identify kinases that may serve as targets for promoting neurite outgrowth as well as others whose targeting should be avoided. We found that compounds that inhibit multiple targets (polypharmacology) promote robust neurite outgrowth in vitro. One compound with exemplary polypharmacology was found to promote axon growth in a rodent spinal cord injury model. A more general applicability of our approach is suggested by its ability to deconvolve known targets for a breast cancer cell line as well as targets recently shown to mediate drug resistance.

[1]  Stephan C. Schürer,et al.  Kinome-wide Activity Modeling from Diverse Public High-Quality Data Sets , 2013, J. Chem. Inf. Model..

[2]  Chris H. Q. Ding,et al.  Minimum redundancy feature selection from microarray gene expression data , 2003, Computational Systems Bioinformatics. CSB2003. Proceedings of the 2003 IEEE Bioinformatics Conference. CSB2003.

[3]  K. Jacobson,et al.  Phosphorylation of paxillin by p 38 MAPK is involved in the neurite extension of PC-12 cells , 2004 .

[4]  L. Mosyak,et al.  Structure-based optimization of PKCθ inhibitors , 2007 .

[5]  Stephan C. Schürer,et al.  Kinome-wide activity models from diverse high-quality datasets , 2013 .

[6]  James S. Duncan,et al.  Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. , 2015, Cell reports.

[7]  K. Jacobson,et al.  Phosphorylation of paxillin by p38MAPK is involved in the neurite extension of PC-12 cells , 2004, The Journal of cell biology.

[8]  David Page,et al.  Relational Differential Prediction , 2012, ECML/PKDD.

[9]  Do-Hun Lee,et al.  Mammalian Target of Rapamycin's Distinct Roles and Effectiveness in Promoting Compensatory Axonal Sprouting in the Injured CNS , 2014, The Journal of Neuroscience.

[10]  K. Schlingensiepen,et al.  Inhibition of P185(C-ERBB-2) protooncogene expression by antisense oligodeoxynuleotides down regulates P185 associated tyrosine kinase activity and strongly inhibits mammary tumor cell proliferation , 1994 .

[11]  S. Strittmatter,et al.  Axonal growth therapeutics: regeneration or sprouting or plasticity? , 2008, Trends in Neurosciences.

[12]  Krister Wennerberg,et al.  Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. , 2013, Cancer discovery.

[13]  A. Hopkins Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[14]  Theonie Anastassiadis,et al.  Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity , 2011, Nature biotechnology.

[15]  John L. Bixby,et al.  High content screening of cortical neurons identifies novel regulators of axon growth , 2010, Molecular and Cellular Neuroscience.

[16]  Stephan C Schürer,et al.  Chemical interrogation of the neuronal kinome using a primary cell-based screening assay. , 2013, ACS chemical biology.

[17]  D. Swinney,et al.  How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.

[18]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[19]  Gavin Harper,et al.  Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. , 2008, Journal of medicinal chemistry.

[20]  W. Young Spinal Cord Regeneration , 1996, Science.

[21]  J. Peters Polypharmacology - foe or friend? , 2013, Journal of medicinal chemistry.

[22]  Helmut Mack,et al.  Rho kinase, a promising drug target for neurological disorders , 2005, Nature Reviews Drug Discovery.

[23]  M. Heisenberg,et al.  P90 Ribosomal s6 kinase 2 negatively regulates axon growth in motoneurons , 2009, Molecular and Cellular Neuroscience.

[24]  Simon K. Mencher,et al.  BMC Clinical Pharmacology BioMed Central Debate , 2005 .

[25]  S. Günther,et al.  Targeting the BET family for the treatment of leukemia. , 2014, Epigenomics.

[26]  Pierre E Ilouga,et al.  High Content Screening Analysis in R , 2013 .

[27]  J. Schwab,et al.  The Rho/ROCK pathway mediates neurite growth-inhibitory activity associated with the chondroitin sulfate proteoglycans of the CNS glial scar , 2003, Molecular and Cellular Neuroscience.

[28]  K. Shokat,et al.  Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.

[29]  O. Steward,et al.  Advances in the Management of Spinal Cord Injury , 1998, The Journal of the American Academy of Orthopaedic Surgeons.

[30]  Yishi Jin,et al.  S6 Kinase Inhibits Intrinsic Axon Regeneration Capacity via AMP Kinase in Caenorhabditis elegans , 2014, The Journal of Neuroscience.

[31]  Zhigang He,et al.  PKC mediates inhibitory effects of myelin and chondroitin sulfate proteoglycans on axonal regeneration , 2004, Nature Neuroscience.

[32]  P. Cohen,et al.  The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.

[33]  Kevan M. Shokat,et al.  Chemical genetic discovery of targets and anti-targets for cancer polypharmacology , 2012, Nature.

[34]  Albert-László Barabási,et al.  Controllability of complex networks , 2011, Nature.

[35]  K. Strebhardt,et al.  Rational combinations of siRNAs targeting Plk1 with breast cancer drugs , 2007, Oncogene.

[36]  B. Tang,et al.  Axonal regeneration in adult CNS neurons – signaling molecules and pathways , 2006, Journal of neurochemistry.

[37]  Kaj Blennow,et al.  Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers , 2013, Nature Reviews Neurology.

[38]  Vance P Lemmon,et al.  Kinase/phosphatase overexpression reveals pathways regulating hippocampal neuron morphology , 2010, Molecular systems biology.

[39]  L. Tsai,et al.  The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. , 1996, Genes & development.

[40]  P. Hajduk,et al.  Navigating the kinome. , 2011, Nature chemical biology.

[41]  Xiao-Ming Xu,et al.  Cortical PKC inhibition promotes axonal regeneration of the corticospinal tract and forelimb functional recovery after cervical dorsal spinal hemisection in adult rats. , 2014, Cerebral cortex.

[42]  G. Terstappen,et al.  Target deconvolution strategies in drug discovery , 2007, Nature Reviews Drug Discovery.

[43]  R. Huber,et al.  Structure-based optimization of novel azepane derivatives as PKB inhibitors. , 2004, Journal of medicinal chemistry.

[44]  G. Superti-Furga,et al.  Stereospecific targeting of MTH1 by (S)-crizotinib as anticancer strategy , 2014, Nature.

[45]  P. Nicotera,et al.  Identification of new kinase clusters required for neurite outgrowth and retraction by a loss-of-function RNA interference screen , 2008, Cell Death and Differentiation.

[46]  S. Okuno Mammalian target of rapamycin inhibitors in sarcomas , 2006, Current opinion in oncology.

[47]  Krister Wennerberg,et al.  Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies , 2014, Scientific Reports.

[48]  L. Benowitz,et al.  Combinatorial treatments for promoting axon regeneration in the CNS: Strategies for overcoming inhibitory signals and activating neurons' intrinsic growth state , 2007, Developmental neurobiology.

[49]  P. Cohen,et al.  The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.

[50]  Garry P Nolan,et al.  What's wrong with drug screening today. , 2007, Nature chemical biology.

[51]  S. Frantz Drug discovery: Playing dirty , 2005, Nature.

[52]  T. Willson,et al.  Seeding Collaborations to Advance Kinase Science with the GSK Published Kinase Inhibitor Set (PKIS) , 2014, Current topics in medicinal chemistry.

[53]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[54]  K. Kaestner,et al.  KLF Family Members Regulate Intrinsic Axon Regeneration Ability , 2009, Science.

[55]  Aideen Long,et al.  Statistical methods for analysis of high-throughput RNA interference screens , 2009, Nature Methods.